Biogen Idec Management Discusses Q2 2012 Results - Earnings Call Transcript
Seeking Alpha
Moving on to daclizumab. We completed enrollment in this side, the second registrational trial for daclizumab and relapsing-remitting MS with more than 1800 patients. The trial will determine whether the significant reduction in annualized relapses and ...
CORRECTING and REPLACING Biogen Idec Increases Revenue 18% to $1.4 ...MarketWatch (press release)
Biogen Idec sees revenue surge on MS drug salesMedical Marketing and Media

all 45 news articles »